Treatment interventions
Women with POP received SHR-1222 or a matching placebo subcutaneously at doses of 100, 200, or 300 mg once monthly (QM) and 400 or 600 mg once every 2 months (Q2M) sequentially (Study design. The decision to proceed to the next dosing cohort was made by the safety review committee (SRC) consisting of sponsor representatives and investigators after all subjects in the previous cohort received the study treatment and had been monitored for no less than 36 days after dosing. Treatment was administered to each cohort for a total of 24 weeks (six doses for QM groups or three doses for Q2M groups).For subjects whose baseline serum 25-OHD level was 20–30 ng/mL, a loading dose of 400,000 IU of vitamin D was administered at baseline. All subjects were given daily calcium (500–600 mg) and vitamin D